0
Détail d'une collection
|
|
Documents disponibles dans la collection (5)
Ajouter le résultat dans votre panier Affiner la rechercheCause-specific mortality in COPD subpopulations: a cohort study of 339 647 people in England / Hannah Whitthaker (2023)
Titre : Cause-specific mortality in COPD subpopulations: a cohort study of 339 647 people in England Type de document : document électronique Auteurs : Hannah Whitthaker, Auteur ; Kieran J. Rothnie, Auteur ; Jennifer K. Quint, Auteur Editeur : Thorax Année de publication : 2023 Collection : Thorax Importance : 7 p. [epub ahead of print] Langues : Anglais (eng) Catégories : [PROMOSAN] BPCO
[TABAC] étude:statistique:mortalité
[TABAC] tabagisme:pathologie:pathologie respiratoire:broncho-pneumopathie chronique obstructiveIndex. décimale : BP 2.1. Mortalité Résumé : Background Identifying correlates of cause-specific mortality in patients with chronic obstructive pulmonary disease (COPD) may aid the targeting of therapies to reduce mortality. We determined factors associated with causes of death in a primary care COPD population.
Methods Clinical Practice Research Datalink Aurum was linked to Hospital Episode Statistics and death certificate data. People with COPD alive between 1 January 2010 and 1 January 2020 were included. Patient characteristics were defined before the start of follow-up: (a) frequency and severity of exacerbations; (b) emphysema or chronic bronchitis; (c) Global Obstructive Lung Disease (GOLD) groups A–D; and (d) airflow limitation. We used Cox Proportional Hazards regression and competing risks to investigate the association between patient characteristics and risk of all-cause, COPD and cardiovascular (CV) mortality.
Results 339 647 people with COPD were included of which 97 882 died during follow-up (25.7% COPD related and 23.3% CV related). Airflow limitation, GOLD group, exacerbation frequency and severity, and COPD phenotype were associated with all-cause mortality. Exacerbations, both increased frequency and severity, were associated with COPD-related mortality (≥2 exacerbations vs none adjusted HR: 1.64, 1.57–1.71; 1 severe vs none adjusted HR: 2.17, 2.04–2.31, respectively). Patients in GOLD groups B–D had a higher risk of COPD and CV mortality compared with GOLD group A (GOLD group D vs group A, adjusted HR for COPD mortality: 4.57, 4.23–4.93 and adjusted HR for CV mortality: 1.53, 1.41–1.65). Increasing airflow limitation was also associated with both COPD and CV mortality (GOLD 4 vs 1, adjusted HR: 12.63, 11.82–13.51 and adjusted HR: 1.75, 1.60–1.91, respectively).
Conclusion Poorer airflow limitation, worse functional status and exacerbations had substantial associations with risk of all-cause mortality. Differing results for CV and COPD-related mortality suggests interventions to prevent mortality may need to target particular characteristics or time points in the disease course.En ligne : http://dx.doi.org/10.1136/thorax-2022-219320 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9948 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Cherry-flavoured electronic cigarettes expose users to the inhalation irritant, benzaldehyde Type de document : document électronique Auteurs : Leon Kosmider, Auteur ; Andrzej Sobczak, Auteur ; Adam Prokopowicz, Auteur Editeur : Thorax Année de publication : 2016 Collection : Thorax num. 71:4 Importance : p. 376-377 Langues : Anglais (eng) Catégories : [TABAC] chimie du tabac:constituant:additif:agent de saveur
[TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électroniqueMots-clés : arômes Index. décimale : TA 3.2.2.4 Pathologies respiratoires (sauf 3.2.2.1, 3.2.2.2, 3.2.2.3) En ligne : https://thorax.bmj.com/content/71/4/376 Format de la ressource électronique : Page de l'éditeur Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9563 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Health effects associated with smokeless tobacco : a systematic review Type de document : texte imprimé Auteurs : J.A. Critchley, Auteur ; B. Unal, Auteur Editeur : Thorax Année de publication : 2003 Collection : Thorax num. 58 Importance : p.435-443 Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] tabagisme:évaluation du tabagisme:test médical
[TABAC] tabagisme:risqueIndex. décimale : TA 1.2 Tabac non fumé Résumé : On pense que les risque pour la santé associés à l'usage du tabac non fumé sont plus bas que ceux encourus en fumant des cigarettes. Une revue systématique a donc été menée pour résumer ces risques. En ligne : http://thorax.bmj.com/content/58/5/435.long Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=3012 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Smoking cessation guidelines for health professionals : an update Type de document : document électronique Auteurs : Robert West, Auteur ; Ann Mcneill, Auteur ; Martin Raw, Auteur Editeur : Thorax Année de publication : 2000 Collection : Thorax num. 55 Importance : p.987-999 Langues : Anglais (eng) Catégories : [TABAC] prévention:recommandation
[TABAC] prévention:santé:éducation pour la santé:rôle du professionnel de santé
[TABAC] sevrage tabagiqueIndex. décimale : TA 0.3 Modes d'action des professionnels Résumé : This paper updates the evidence base and key recommendations of the Health Education Authority (HEA) smoking cessation guidelines for health professionals published in Thorax in 1998. The strategy for updating the evidence base makes use of updated Cochrane reviews supplemented by individual studies where appropriate. This update contains additional detail concerning the effectiveness of interventions as well as comments on issues relating to implementation. The recommendations include clarification of some important issues addressed only in general terms in the original guidelines. The conclusion that smoking cessation interventions delivered through the National Health Service are an extremely cost effective way of preserving life and reducing ill health remains unchanged. The strategy recommended by the guidelines involves:
(1) GPs opportunistically advising smokers to stop during routine consultations, giving advice on and/or prescribing effective medications to help them and referring them to specialist cessation services;
(2) specialist smokers' services providing behavioural support (in groups or individually) for smokers who want help with stopping and using effective medications wherever possible;
(3) specialist cessation counsellors providing behavioural support for hospital patients and pregnant smokers who want help with stopping;
(4) all health professionals involved in smoking cessation encouraging and assisting smokers in use of nicotine replacement therapies (NRT) or bupropion where appropriate. The key points of clarification of the previous guidelines include:
(1) primary health care teams and hospitals should create and maintain readily accessible records on the current smoking status of patients;
(2) GPs should aim to advise smokers to stop, and record having done so, at least once a year;
(3) inpatient, outpatient, and pregnant smokers should be advised to stop as early as possible and the advice recorded in the notes in a readily accessible form;
(4) there is currently little scientific basis for matching individual smokers to particular forms of NRT;
(5) NHS specialist smokers' clinics should be the first point of referral for smokers wanting help beyond what can be provided through brief advice from the GP;
(6) help from trained health care professionals specialising in smoking cessation such as practice nurses should be available for smokers who do not have access to specialist clinics;
(7) the provision of specialist NHS smokers' clinics should be commensurate with demand; this is currently one or two full time clinics or their equivalent per average sized health authority, but demand may rise as publicity surrounding the services increases.En ligne : https://doi.org/10.1136%2Fthorax.55.12.987 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10351 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Varenicline versus transdermal nicotine patch for smoking cessation : results from a randomised, open-label trial Type de document : texte imprimé Auteurs : Henri-Jean Aubin, Auteur ; Alex Bobak, Auteur ; John Britton, Auteur Editeur : Thorax Année de publication : 08/02/2008 Collection : Thorax Importance : 8 p. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:efficacité du sevrage
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : La varénicline, un nouveau traitement pour la cessation tabagique, a démontré de manière significative une plus grande efficacité sur le placebo et le bupropion. Une étude a été menée pour comparer un régime de 12 semaines à la varénicline en parallèle avec un régime de 10 semaines d'une thérapie de remplacement nicotinique transcutanée standard pour le sevrage tabagique. En ligne : https://thorax.bmj.com/content/63/8/717.long Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=3011 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
